Most genetic studies search one trait at a time. This one asked whether any variants move several cardiometabolic markers together in the same 11,693-person cohort — and found a locus that raises LDL cholesterol while lowering CRP, an awkward result for treating either marker in isolation.
Solid lines are connections this site curates. Dashed lines mean the two ends share a research paper — worth knowing, and not a claim that one explains the other.
Most genetic studies pick a single trait — LDL cholesterol, say — and search for variants that move it. Middelberg et al. 2011 asked a different question: analysed jointly, in the same people, do any genetic variants move more than one cardiometabolic marker at once? Thirteen biochemical traits went into the analysis: liver enzymes (ALT, AST, GGT), butyrylcholinesterase, C-reactive protein (CRP), ferritin, glucose, HDL and LDL cholesterol, insulin, triglycerides, uric acid, and body mass index.
The cohort was large and structured: 2,548 adolescents and 9,145 adults from 4,986 Australian twin families — 11,693 people in total, related to each other in known ways, which is itself a useful design for separating genetic from environmental contributions.
Multivariate analysis found eight loci influencing more than one trait at once; univariate analysis confirmed two of them at full genome-wide significance — LPL (chromosome 8, moving HDL and triglycerides together) and the TOMM40/APOE-C1-C2-C4 cluster (chromosome 19, moving LDL and CRP together). A third, OASL (chromosome 12), affected GGT, LDL and CRP.
The paper's most unexpected finding: the chromosome 12 and chromosome 19 loci moved LDL cholesterol and CRP in opposite directions. That is worth flagging on its own terms — CRP is increasingly used as a cardiovascular risk marker in its own right, not only an inflammation marker, which makes a locus that raises LDL while lowering CRP (or the reverse) a genuinely awkward result for any single-number risk score built from either marker alone. The study also validated seventeen previously reported loci from earlier, single-trait work.
The six variants on this page come from that same joint effort. LPL's role is stated directly in the paper: HDL and triglycerides. The others — APOB, BCHE, PCSK7, SLC17A4, and a locus near ZNF518B — are reported here without individually re-deriving each one's specific trait assignment beyond what the source study establishes. The honest and useful thing this page can say about all six is the same: each moved more than one cardiometabolic marker in the same large, related cohort, which is a different and rarer kind of finding than a typical single-trait GWAS hit.
None of the six variants here are used clinically to guide treatment. Cardiovascular risk assessment in practice uses the measured values themselves — LDL, HDL, triglycerides, CRP, blood pressure, glucose — not genotypes at these positions. This page is about what a joint-analysis study design revealed, not a new risk tool.
The opposite-direction LDL/CRP finding is a useful caution rather than an actionable one: it is a reminder that a single genetic variant can look protective on one marker and harmful on another, which is exactly why clinical risk assessment still relies on measuring the actual markers in a given person rather than inferring them from genotype.
Cholesterol, blood pressure, glucose and inflammatory markers each have their own, more focused pages elsewhere on this catalogue, built from studies that examined one trait at a time. This page is deliberately about what changes when several are studied together instead.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Cardiovascular Disease Risk Factors comes down to these specific, well-studied positions — not a diagnosis.
The studies behind these variants recruited participants from different ancestries — a result found in one population doesn't always transfer to another. Based on 6 of 6 linked studies with a resolved discovery ancestry.
Databases, guidelines and references
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Cardiovascular Disease Risk Factors. MyGeneLog™. https://www.mygenelog.com/conditions/cardiovascular-disease-risk-factors
No. Clinical risk assessment uses measured values — LDL, HDL, triglycerides, CRP, blood pressure, glucose — directly, not genotypes at these six positions. This page describes a study design finding, not a risk tool.
Because the source study itself analysed thirteen biochemical traits jointly in the same people, specifically to find variants moving more than one marker at once — a different design from most single-trait GWAS. Splitting the result back into six unrelated single-trait pages would misrepresent what the study actually did.
It means the same genetic variant is associated with higher LDL cholesterol and lower CRP (or the reverse) in this cohort — an unexpected result the paper highlights because CRP is increasingly used as a cardiovascular risk marker in its own right. It is a caution about relying on any single marker in isolation, not something with an individual action to take.
No — most other pages here come from studies of one trait (cholesterol, blood pressure) at a time. This page is specifically about what a joint, multi-trait analysis found when thirteen markers were examined together in the same large cohort.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog™. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.